- NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential therapy of most cancers
- NGM120 has been effectively tolerated up to now in sufferers in the Phase 1b mixture cohort (NGM120 + gemcitabine + Nab-paclitaxel) with no dose-limiting toxicities
- As of the March 15, 2022 summary information closing date, amongst the six evaluable sufferers in the Phase 1b mixture cohort, a illness management fee of 100% was noticed, median progression-free survival had not been reached and the 12-month survival fee was 83.3%
- Three of the six evaluable sufferers skilled partial responses (PR) extending greater than 32 weeks as of the summary closing date, together with one affected person with a PR that was ongoing at 90 weeks as of August 15, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology firm targeted on discovering and growing transformative therapeutics for sufferers, at present introduced that up to date preliminary findings from its Phase 1b dose escalation trial of NGM120, a novel GFRAL antagonist antibody drug candidate, in sufferers with metastatic pancreatic most cancers are being introduced at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer, on Wednesday, September 14, 2022. These outcomes exhibit that therapy with the drug was effectively tolerated up to now in the research with no dose-limiting toxicities and supplied encouraging alerts of anti-cancer exercise in sufferers with metastatic pancreatic most cancers.
The presentation titled “Initial Results of a Cohort of Advanced Pancreatic Cancer Patients in a Phase 1b Study of NGM120, a First-in-Class Anti-GDNF Family Receptor Alpha Like (GFRAL) Antibody” is obtainable to convention attendees for the length of the AACR Special Conference: Pancreatic Cancer and shall be archived on the ‘Presentations and Publications’ web page of NGM Bio’s web site right here.
The summary’s first writer, Andrew Hendifar, M.D., Cedars-Sinai, Samuel Oschin Cancer Center, commented, “The preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort merit attention. Historic median progression-free survival in this patient population is approximately 5-7 months. While a small sample size, seeing two patients in this cohort exhibit partial response beyond 17 months is intriguing. I look forward to further clinical study of NGM120.”
“While preliminary, these findings encourage further study of NGM120 for the treatment of patients with advanced pancreatic cancer, a disease for which better therapeutic options are needed for patients,” mentioned Alex DePaoli, M.D., Senior Vice President, Chief Translational Officer at NGM.
In addition to the Phase 1b dose escalation trial of NGM120 together with gemcitabine and Nab-paclitaxel in sufferers with metastatic pancreatic most cancers, NGM Bio is conducting a Phase 2 randomized, single-blind (investigator-blinded), placebo-controlled, multi-center growth trial of NGM120 together with gemcitabine and Nab-paclitaxel as a first-line therapy in sufferers with metastatic pancreatic most cancers (known as the PINNACLES trial), a Phase 1a trial testing NGM120 as a monotherapy for the therapy of sufferers with strong tumors and a lately initiated Phase 1b trial testing NGM120 together with a number of traces of hormone therapies in sufferers with metastatic castration-resistant prostate most cancers (mCRPC).
NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic issue receptor alpha-like (GFRAL) and inhibits development differentiation issue 15 (GDF15) signaling. NGM Bio scientists have made a number of necessary discoveries associated to GDF15, together with identification of its cognate receptor, GFRAL. Evidence has proven that serum ranges of GDF15 are elevated in sufferers with a number of tumor sorts, together with non-small cell lung most cancers, melanoma, pancreatic, prostate, colorectal, gastric, esophageal and ovarian most cancers, and are related to a worse prognosis. For extra particulars on NGM Bio’s oncology portfolio go to NGM Bio’s web site at https://www.ngmbio.com/discovery-engine/oncology/.
About NGM Bio
NGM Bio is concentrated on discovering and growing novel, life-changing medicines for folks whose well being and lives have been disrupted by illness. The firm’s biology-centric drug discovery method goals to seamlessly combine interrogation of advanced disease-associated biology and protein engineering experience to unlock proprietary insights which are leveraged to generate promising product candidates and allow their fast development into proof-of-concept research. As explorers on the frontier of life-changing science, NGM Bio aspires to function certainly one of the best analysis and improvement engines in the biopharmaceutical trade. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, at all times led by biology and motivated by unmet affected person want. Today, the firm has seven applications in scientific improvement, together with 4 in Phase 2 or 2b research, throughout three therapeutic areas: most cancers, retinal illnesses and liver and metabolic illnesses. Visit us at www.ngmbio.com for extra info.
Forward-Looking Statements
Statements contained on this press launch relating to issues that aren’t historic info are “forward-looking statements” inside the which means of the Private Securities Litigation Reform Act of 1995. Words resembling “will,” “look forward,” “potential,” “promising,” “preliminary,” “encouraging,” ”intriguing,” “aspires,” “aims” and related expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) are supposed to establish forward-looking statements. These statements embody these associated to: NGM Bio’s product candidates, together with the potential of NGM Bio’s oncology product candidate, NGM120 to deal with most cancers; potential outcomes instructed by preliminary findings relating to NGM120; NGM Bio’s aspiration to function certainly one of the best analysis and improvement engines in the biopharmaceutical trade and different statements that aren’t historic truth. Because such statements take care of future occasions and are primarily based on NGM Bio’s present expectations, they’re topic to varied dangers and uncertainties, and precise outcomes, efficiency or achievements of NGM Bio might differ materially from these described in or implied by the statements on this press launch. These forward-looking statements are topic to dangers and uncertainties, together with, with out limitation, dangers and uncertainties related to the expensive and time-consuming pharmaceutical product improvement course of and the uncertainty of scientific success, together with dangers associated to failure or delays in efficiently initiating, enrolling, reporting information from or finishing scientific research, in addition to the dangers that outcomes obtained in preclinical or scientific trials up to now will not be indicative of outcomes obtained in ongoing or future trials, that preliminary outcomes will differ from last outcomes and that NGM Bio’s product candidates might in any other case not be tolerable and efficient therapies of their deliberate indications; the ongoing COVID-19 pandemic, which has adversely affected, and will materially and adversely have an effect on in the future, NGM Bio’s business and operations, together with NGM Bio’s capability to well timed provide, provoke, enroll and full its ongoing and future scientific trials; the time-consuming and unsure regulatory approval course of; NGM Bio’s reliance on third-party producers for its product candidates and the dangers inherent in manufacturing and testing pharmaceutical merchandise; the sufficiency of NGM Bio’s money sources, together with to fund its wholly-owned applications, and NGM Bio’s want for added capital; and different dangers and uncertainties affecting NGM Bio and its improvement applications, together with these mentioned in the part titled “Risk Factors” in NGM Bio’s annual report on Form 10-Q for the quarter ended June 30, 2022 filed with the United States Securities and Exchange Commission (SEC) on August 4, 2022 and future filings and studies that NGM Bio makes from time to time with the SEC. Except as required by regulation, NGM Bio assumes no obligation to replace these forward-looking statements, or to replace the causes if precise outcomes differ materially from these anticipated in the forward-looking statements.
